Sessions

Session Descriptions

Presentations must focus on basic and applied research conducted in specific chemical and biological defense areas, which are listed below. The conference is particularly interested in innovations and developments yet to be introduced to the defense community.

The CBD S&T Conference will consist of parallel sessions Tuesday, November 28 continuing through the day on Thursday, November 30. The Poster Session will kick off Tuesday evening and continue through Wednesday evening. Please view the list of session descriptions below:

A Modeling & Simulation Framework for Comprehensive CBDP Decision Support

DTRA Session Chair: Dr. John Hannan

Modeling and Simulation efforts abound within the CBDP, the DoD, and the USG writ large.  However, most capabilities exist largely as stand-alone, seldom coupled within a unified framework allowing for comprehensive analytical use.  This session seeks presentations that explore the concept of a Modeling & Simulation Framework to support a broad spectrum of CBDP activities to include trade space analyses for acquisition decisions to simulation-based studies to augment requirement refinement processes.

Advances in Fundamental Materials Research

DTRA Session Chair(s): Ms. Tracee Whitfield & Dr. Glenn Lawson

This topic area focuses on the development of novel materials that can protect people, electronics, and vehicles and reduce the burden on personnel and support systems. These new materials will ideally provide greater levels of protection for personnel, enable rapid regeneration and reconfiguration for multipurpose use, and be biodegradable and compostable. Areas of research include, but are not limited to, dynamic multifunctional materials that respond to threats and continually optimize between protection and burden, self-detoxifying materials for protective clothing, and development of candidate coatings with higher efficacy to resist, absorb or catalyze threat agents.

Advances in Hazard Mitigation

DTRA Session Chair(s): Dr. Glen Lawson & Mr. William Buechter

This topic areas focuses on the optimization of decontamination formulation chemistry and application processes for chemical and biological hazard mitigation.  Hazard mitigation delivers solutions that protect the warfighter by neutralizing the threat upon exposure or through decontamination; thereby mitigating the spread of contamination, minimizing exposure, allowing personnel to reduce MOPP levels.  Technology and capabilities of interest are those that enhance survival through increased effectiveness and responsiveness of decontamination with reduced logistical overhead, render threats harmless without harming personnel or materiel, and demonstrate improved efficacy across a broad range of threats. Example areas of interest include reducing or eliminating CBRN contamination of sensitive equipment and non-sensitive equipment including vehicles, aircraft, maritime vessels, fixed sites, hazardous waste and other major end items and supplies, coatings with the capability to react to mitigate exterior contamination, and products with the capability to clean and/or recycle effluent contamination runoff.

Advances in Fieldable Chemical Threat Sensing

DTRA Session Chair: Dr. Anthony Esposito

When encountering unknown substances in the field, first responders have few simple, low-cost approaches to quickly triage the substance by category (e.g., chemical threats, explosives, narcotics) before taking further action.  The easiest and most rapid approaches include paper test strips (pH, M8, oxidizer) but these have limited libraries and color interpretation issues. Innovative technologies are sought to rapidly cover a wide range of threats encountered by warfighters and first responders, to ideally include, or be expandable to: (i) Chemical warfare agents (CWAs) and precursors (ii) Toxic industrial chemicals (TICs) (iii) Explosives and explosives precursors (iv) Narcotics. Detection approaches that reduce cost, complexity, and logistical burden are of highest interest.

Advances in Protection

DTRA Session Chair(s): Mr. Salvatore Clementi & Dr. Charles Bass

This topic area focuses on development and assessment of advanced materials and system approaches for chemical, biological and radiological protection and hazard mitigation.  DTRA is striving to develop lighter, cooler, smarter, and more effectively integrated physical protection that enables the warfighter to fully complete the mission while protected from CB threats. These products and technology would enhance individual survival by reducing the physical burden of individual protection that can be integrated into the warfighter’s combat ensemble to protect against CBR liquid, vapor, and aerosol hazards from skin, eyes or lungs contact or exposure. Example areas of interest include coatings with the capability to resist or absorb exterior contamination, high efficacy filters able to protect against TICs and CWA, and materials with decreasing thermal burden.

Animal Models for Chemical Agent Toxicity and Medical Countermeasure Development

DTRA Session Chair: Dr. Ali Director-Myska

Background: In September 2016 DTRA and several of its USG Interagency partners sponsored and participated in an Animal Model Development Workshop to explore the scientific and regulatory challenges of developing medical countermeasures (MCM) under the FDA "Animal Rule" (21 CFR 314.600 for drugs; 21 CFR 601.90 for biological products). The goals of this workshop were to highlight the significant progress made in animal model development for CBRN MCMs, review recent case studies of products under development using animal models, and capture lessons learned to inform future animal model development efforts. In addition, the workshop provided a forum to discuss current challenges and identify potential solutions or mitigation strategies.  While the workshop focused generally on the “Animal Rule,” the specific case studies dealt with issues surrounding the using of animal models for Rad/Nuc and Bio. 

In addition to this workshop, DTRA and several of its USG Interagency partners stood up working groups to engage the chemical agent medical countermeasure (NA MCM) community in technical and scientific discussions, broaching topics of interest to both civilian and military sponsors, in a non-product specific manner, to identify common strategies for moving products through development pipelines.  The goal of these working groups to attract participation from subject matter experts within academia, industry, government, and the Food and Drug Administration (FDA).  Of these working groups, the most advanced is, Interagency Nerve Agent Forum for Medical Countermeasure Developers (INFORMED). 

This session will focus on what the various agencies interests, needs, requirements and questions are relative to the development of animal models for use in medical chemical countermeasures research, development, testing and evaluation. 

Beyond Plates: Rapid, Automated Diagnosis of Antimicrobial Resistance

DTRA Session Chair: Dr. Diane Dutt

The rising challenge of antimicrobial resistance is estimated to cost 10 million lives a year by 2050. The biodefense hazards of antimicrobial resistance can be expected to rise apace. This crisis must be confronted not only with new antimicrobials themselves but also with new diagnostic tools that allow our antimicrobial arsenal to be deployed more effectively. The gold standard method of identifying susceptibility to antimicrobials requires use of a clinical laboratory and could take up to 48 hours for a determination to be made; a literal lifetime for those battling the most dangerous pathogens. New diagnostic approaches and technologies are urgently needed to confront the challenge of antimicrobial resistance. JSTO’s goal is to develop diagnostics for antimicrobial susceptibility that are rapid (under 6 hours), phenotypic, portable, and work directly from a clinical sample. This topic seeks abstracts addressing paths to this goal.

Biosurveillance Ecosystem (BSVE)

DTRA Session Chair: Dr. Chris Kiley

The BSVE is a virtual, customizable, collaborative system that leverages existing commercial and government technologies. The BSVE ingests a wide variety of data sources: open source data; social media, point-of-need diagnostic data; and DoD, Interagency, national and international surveillance system data. Analytic applications "apps" within the BSVE (and user-designed apps) use the aggregated data streams to provide near-real-time modeling, analyses, and visualized results. The BSVE supports the biosurveillance analysts' and decision-makers' needs by providing automated, intelligently suggested data, tools, and analyses. The BSVE also provides a user-friendly interface with modern collaboration and reporting features.

This topic seeks presentations which highlight the functionality and utility of the data and analytic applications available within the BSVE.

Broad Spectrum Medical Countermeasures against Biological Toxins

DTRA Session Chair(s): Dr. Traci Pals & Mr. Mike Johnson

Potential topics for this session will focus on broad-spectrum platform technologies that have the ability to provide effective neutralization as a pretreatment, post-exposure prophylactic or therapeutic for the widest range of biological toxins.  Their mechanisms of action are diverse, ranging from blockage of specific molecular reactions or binding to specific receptors, to those acting at multiple sites. Current broad-spectrum treatment options are limited in nearly all cases to supportive and palliative care and developing specific MCMs for all classes of potential bio-toxin threats would be prohibitively expensive. The challenge of achieving this objective may appear to be daunting, but recent advances suggest that it may be possible to engineer biomimetic molecules or nanoparticles as MCMs that can serve this protective function.  These biotoxin MCMs might, for example, absorb, detoxify or block biotoxins from entering human target cells and organs, or activate the body’s natural protective physiological systems.

Wearable Physiological Monitoring Technologies for Earlier Warning of Health Changes

DTRA Session Chair: Mr. Ed Argenta

The CB-VIEW aims to broaden and enhance the current Biosurveillance Ecosystem (BSVE) architecture and technologies to provide improved Chemical and Biological Defense (CBD) situational awareness, a common analytical work bench for users, integration and fusion of a wide array of relevant data sources, and decision support tools for the tactical to strategic level command authorities.
This topic seeks presentations describing decision support tools for the tactical to strategic level command authorities which are based on the following novel data sources:

  • Wearable devices for earlier warning and triage
  • Genomic and transcriptomic signatures for outbreak severity prediction
  • Unmanned Aerial Vehicles (UAV) for earlier warning and hazard prediction

Presentations should discuss how the data are acquired, synchronized, stored, and transmitted from the warfighter to the decision engine.

Chemical Sensing of Obscured Threats

DTRA Session Chair: Dr. Anthony Esposito

Sensing capabilities for situational awareness of denied access spaces can include systems for through barrier detection/identification of hazards, and/or detection in multi-room structures where warfighter access is limited or undesirable.

Field-Forward Diagnostics

DTRA Session Chair: Lt Col Elaine Sumera

Field forward diagnostics are pushing medical evaluation to the ‘point of need’ level.  Sick patients can be tested quickly and easily by non-medical personnel for a multitude of diseases.  Present ideas for new multiplexed field-forward diagnostic technologies.

Consideration should be given toward:
  • Small Point-of-Need devices
  • Multiplexed Capability
  • Incorporation of low risk, rapid, simple and relevant sample collection of clinical matrices

Hazard Prediction and Warning

DTRA Session Chair: Mr. Rick Fry

The goal of DTRA's CBRN Hazard Prediction and Warning focus area is to enhance CBRN warfare agent hazard prediction and warning capabilities in support of DTRA Reachback and in fulfillment of JEM and JWARN requirements.

DTRA develops analysis products related to hazard prediction and warning for transition to JPEO and other stakeholders to aid in decision-making and program planning.  We invite presentations demonstrating:  1) emerging hazard prediction and warning modeling tools in support of decision-making and program planning for CBRN defense, 2) innovative techniques for predicting initial hazards, exposures, casualties, and infections and 3) new methods for enabling timely and accurate warnings and intelligent responses.

Host-Based Biomarkers for Early Diagnosis of Exposure or Infection

DTRA Session Chair: Dr. Nate Adams

By the time a person exhibits symptoms and seeks medical attention, they have likely already spread the disease or threat agent to someone else. What if we could use early human host biomarkers to identify, diagnose and treat early and prevent prophylaxis misuse or even the next outbreak? JSTO is seeking to analyze clinical specimens and develop in vitro diagnostic devices for differentially expressed molecules, proteins and genes as early indicators of disease and Chemical-Biological Warfare Agent exposure.

Some areas include:
  • Rapidly distinguishing between bacterial versus viral infections
  • Classifying pathogenicity – e.g. identify gram-positive or gram-negative bacteria to prevent antibiotic misuse
  • Identifying early biomarkers of military-relevant disease, BWA and CWA exposure
  • Using molecular biomarkers to predict infectious disease transmission potential

Immune Modeling for Vaccine Development

DTRA Session Chair: Dr. Ashley Triplett

This session will focus on current strategies in systems biology and computational immunology used to predict and design immunogens, model immune responses to vaccination, and bridge animal and human immunological data. Immune responses elicited by vaccination or infection, and across species, is extremely complex and diverse. Computational modeling methods, however, hold great promise to deepen our understanding of this dynamic system as they have already provided novel insights into various aspects of immune system function, including antibody production and maturation/somatic mutation; T cell development, activation and differentiation, generation and maintenance of memory responses, and host-pathogen interactions. Continuous development and refinement of computational immunology methods can lead to more predictive capabilities to facilitate identification of immune correlates of protection for effective vaccines as well as an understanding of why a vaccine candidate may be less effective. The goal of this session is to provide attendees with information on the current capabilities of these methods and how computational tools can be utilized to assist in vaccine developmental efforts.

Innovations in On-demand, Forward-deployable Manufacturing of Medical Countermeasures

DTRA Session Chair: Dr. David Hone

This session will review the current art-of-the-possible, and explore opportunities and hurdles that pave the road to successful utilization of first generation systems under simulated live-fire test & evaluation settings.

Integrated Approach to Diagnostics for Chemical Warfare Agent Exposure

DTRA Session Chair: Dr. Brian Pate

Approaches to cueing, field diagnosis, and definitive analytics pertinent to chemical warfare agent exposure.  Focus is on concepts of employment within chemical warfare scenarios as well as novel approaches to (a) making definitive methods for confirming chemical warfare agent exposure more rapid and fieldable; (b) making point-of-need diagnostics assays for chemical exposure more definitive and continuous; and (c) making methods to cue the use of diagnostics more specific and definitive.  These methods may rely on improved understanding of physiological signs and symptoms as well as advances in discovery of agent- and host-based biomarkers as well as supporting enabling science.

Machine Learning for CB Sensing

DTRA Session Chair: Ms. Kathleen Quinn

Can sensing equipment learn and modify its algorithms to assess whether an unknown is hazardous before disruption of operations is observed? This topic can include use of ‘library-less’ sensors or smart sensors capable of on the fly algorithm modifications.

Medical Countermeasures to Address Intracellular Bacterial Pathogens

DTRA Session Chair(s): Drs. Amanda Horstman-Smith & Julie Boylan

This topic seeks discussions on technologies, either established or emerging, that specifically address infection with intracellular bacterial pathogens, with a specific interest in pathogens of biodefense interest.  Responsive countermeasure approaches will also be congruent with developing strategies to combat antimicrobial resistance.  Technologies of interest include, but are not limited to vaccines, host directed therapeutics, immunomodulation, and novel therapeutic modalities.  Please note, targeted delivery systems and novel formulations are outside the scope of this topic.

Nanotechnology Advancements with Potential Counter-WMD Applications

DTRA Session Chair: Dr. Akbar Khan       

JSTO is interested in innovative talks on emerging Nanotechnology applications to countering chemical and biological threats. Nanotechnology is the understanding and control of matter at dimensions between approximately 1 and 100 nanometers, where unique phenomena enable novel applications. Work within the intersecting disciplines at the core of nanotechnology innovation-including physical, life, and social sciences and engineering-has revealed the potential of engineered nanomaterials (ENMs) and nanoscale processes to collect and store energy, reinforce materials, sense contaminants, enable life-saving drugs, and shrink and accelerate computational devices in both incremental and paradigm-shifting ways. Further, nanotechnology has enabled development of entirely new materials and devices that can be exploited in each of these and countless other applications.

The United States has set the pace for nanotechnology innovation world-wide with the National Nanotechnology Initiative (NNI). Launched in 2001 with eight agencies, the NNI today consists of the individual and cooperative nanotechnology-related activities of 20 Federal departments and independent agencies with a range of research and regulatory roles and responsibilities. Eleven of the participating agencies have research and development (R&D) budgets that relate to nanotechnology, with the reported NNI budget representing the collective sum of these investments. Funding support for nanotechnology R&D stems directly from NNI agencies, not the NNI. As an interagency effort, the NNI informs and influences the Federal budget and planning processes through its participating agencies and through the National Science and Technology Council (NSTC).   Papers presented in this topic should show linkage with the on-going interagency efforts articulated within the National Nanotechnology Initiative (NNI).

Next Generation Sequencing for Biodefense Applications

DTRA Session Chair: Mr. Charles Hong

Next-Generation Sequencing (NGS), otherwise known as High-throughput Sequencing (HTS), has changed the landscape of biology over the past 10+ years. During this time, NGS has been instrumental in molecularly characterizing biological threats and relevant pathogens of interest to the Chemical Biological Defense Program (CBDP) and the Department of Defense (DoD). NGS is now being utilized as a flexible, accurate, and holistic approach to best enable characterization, detection, and identification of biological threats.  JSTO's goal is to work with our US Government partners and the greater scientific community to evaluate the full breadth of how we can use NGS to help protect the Warfighter.

Some of the NGS applications we are interested include, but not limited to:
  • Developing novel sample preparation capabilities for characterization, detection, and identification of biological threats
  • Utilizing NGS for metagenomic applications in complex clinical and environmental sample matrices
  • Leveraging NGS to enhance and develop diagnostic assays
  • Determining how genomics/bioinformatics can enhance our early warning capabilities
  • Generating cost effective bioinformatic solutions to quickly analyze and easily interpret the staggering amount of complex data generated by NGS studies

Novel Approaches to Medical Countermeasures to Chemical Warfare Agents

DTRA Session Chair: Dr. Brian Pate

The fielded regimen employed as prophylaxis and therapeutics against chemical warfare agent exposure has remained mostly unchanged for decades, even while chemical warfare has persisted as a threat and even while medical technology has exhibited remarkable overall advancements.  This session will explore (a) contributing structural, political, cultural and scientific factors that have limited progress toward improved medical countermeasures to chemical warfare agents and means to address these factors, (b) data-driven means to inform investment decisions, structure programs, and track outcomes pertinent to the goals of this area; (c) novel approaches to improved prophylaxis and treatment for chemical warfare agent exposure.

Operational Effects and Risk Analysis

DTRA Session Chair: Mr. Eric Lowenstein

DTRA seeks presentations describing emerging capabilities to enhance the ability of decision-makers, planners, and the Warfighter to assess CBRN effects on operations, personnel, and equipment and to recommend courses of action to minimize or eliminate threat.  DTRA invites presentations on research furthering an understanding of operational effects and risk in the context of CBRN defense.  We are interested in studies, research, and analyses that provide, or have potential to provide, insight into operational effects and risk with a joint or service-specific perspective.

Phage Therapies for Bacterial Infection

DTRA Session Chair(s): Drs. Amanda Horstman-Smith & Julie Boylan

The utilization of natural or engineered phage as a platform for therapeutic development has long been a promising but, as yet, unrealized approach to treat bacterial infections and, potentially, address antibiotic resistance.  This topic seeks to stimulate discussion around the development and obstacles to development of phage therapies, and means to overcome those obstacles, to include those approaches utilizing phage as the therapeutic or as the vehicle to deliver combination therapeutics.

Predicting Acute Systemic Toxicity of Chemical Agents

DTRA Session Chair: Dr. Ali Director-Myska

Computational Rapid Identification & Scientific Threat Analysis (CRISTAL)

Background: Currently, there are many different software tools that have not been applied to the DoD’s need to assess a compound’s “potential to cause acute, debilitating toxicity.”  Some of these models might provide a valuable backbone for predicting physicochemical properties, environmental fate and acute toxicity.  Many commercial models have been designed for pharmaceutical use in terms of structure-activity prediction, physiologically-based pharmacokinetics/pharmacodynamics, different products have been developed (government and commercial) to forecast physicochemical properties from molecular structure or to utilize fundamental experimental data to determine likely agent fate parameters. 
Upon receipt of “Application of Modern Toxicology Approaches for Predicting Acute Toxicity for Chemical Defense,” (1) the Threat Agent Science (TAS) Program began an analysis of its current program to find where efficiencies could be gained, as well as where in silico approaches were already being employed and developed a program concept which to encompass Predictive Threat Agent Characterization and Toxicology.  This program has been dubbed, “Computational Rapid Identification & Scientific Threat AnaLysis (CRISTAL)”. 

In order to be successful, CRISTAL requires a combination of technical areas to ensure a comprehensive look at the problem which includes: physicochemical properties, chemical disposition and metabolism, through acute toxicity predictions.  A successful approach will require validation steps with available in vitro and in vivo data to support model reliability.

DTRA recently released a topic in its Chem Bio BAA to solicit proposal supporting the development of CRISTAL.  In addition to this topic, DTRA is currently partnering with other US Government Agencies through the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) to develop a roadmap for predicting acute systemic toxicity. 

This session will focus on what the various agencies requirements are for predicting acute systemic toxicity and what their performers are doing to support those requirements. 

Abstracts are sought on the development, implementation and/or integration of “non-testing approaches” (in vitro and/or computational) to predict acute systemic toxicity in laboratory animals and/or humans of chemical agents for operationally relevant routes of exposure (ocular, inhalation (nose-only and whole-body) and dermal) and verify fidelity of assays and/or computations. 

Bibliography
    1.  National Academies of Sciences, Engineering, and Medicine. Application of Modern Toxicology Approaches for Predicting Acute Toxicity for Chemical Defense. Washington,DC: The National Academies Press, 2015. doi:10.17226/21775.
    2.  Katritzky, A. R., Lobanov, V. S., & Karelson, M. (1995). QSPR: the correlation and quantitative prediction of chemical and physical properties from structure. Chem. Soc. Rev., 24(4), 279-287.
    3.  Cherkasov, A., Muratov, E. N., Fourches, D., Varnek, A., Baskin, I. I., Cronin, M., ... & Consonni, V. (2014). QSAR modeling: where have you been? Where are you going to?. Journal of medicinal chemistry, 57(12), 4977-5010.
    4.  National Research Council. Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC: The National Academies Press, 2007. doi:10.17226/11970.

Real Time Autonomous Reconnaissance

DTRA Session Chair: Ms. Kathleen Quinn

Unmanned and/or autonomous ground or aerial CB detection for beyond line of sight identification and tracking of threats without post processing. Systems can include micro to full size UAV sensing at either very low or very high altitudes.

Sample Collection System with Residual Storage

DTRA Session Chair: Ms. Kathleen Quinn

Rapid in-field detectors have the capability to test for preliminary results but utilize the entirety of the sample.  The ability to have a secondary more sensitive test is optimal but if the primary sample has been depleted, it is difficult.  Present abilities/technologies to collect environmental samples for testing but additionally keep a secondary backup.

Science of the Skin and Respiratory Tract, and Related Countermeasures Pertinent to Chemical/Biological Defense

DTRA Session Chair: Dr. Brian Pate

This session will focus on advancements in understanding of molecular partitioning within the respiratory tract, the skin, and the interstitial fluid, changes in these matrices upon exposure, and how this understanding can be coupled with materials fabrication, delivery methods, and logistical considerations to contribute to diagnostics and countermeasure schemes.

Synthetic Biology for Novel Networks

DTRA Session Chair: Dr. Kristen O'Connor

Use of synthetic biology methods to create novel biological networks and materials to sense the environment and report the presence of a chemical or biological agents of interest. Prefer the potential for on-demand sensor optimization to respond to changing needs.

Technical Coordination Working Group for Half a Day to Bring in Scientists Funded by DoD, DHS, EPA and CDC

DTRA Session Chair: Dr. Akbar Khan

DoD, DHS, EPA, and CDC will present in the following collaborative areas:
    (a)  Biodetection & Biosurveillance
    (b)  Bioresponse & Recovery
    (c)   Risk assessment & systems modeling
    (d)  Fundamental properties of biological threats
    (e)  Chemical Defense

Understanding the Blood-Brain Barrier and Neurological Effects within Chemical and Biological Threat Exposure Scenarios

DTRA Session Chair: Dr. Brian Pate

This session will focus on advancements to understanding of changes to the central nervous system and the blood-brain barrier resulting from exposure to chemical and biological warfare agents, as well as improved in-vivo, in-vitro, and in-silico models and imaging science that can contribute to further advancements.

Using Synthetic Biology to Develop Novel Therapies and Understand Threats

DTRA Session Chair(s): Dr. Brian Pate & Mr. Dale Taylor

Potential topics center on identification and exploitation of new synthetic biology tools and methods for the development of novel therapeutics and threat agent science. This includes cell free expression systems, CRISPR CAS-9, gene circuitry, technologies for analyzing biological systems at the genomic, proteomic, and metabolomic levels which are especially valuable in pathway, whole cell, and multi-cell applications, and mathematical modeling tools and computational tools which can dramatically increase the speed of the design process as well as reduce the cost of development. Additionally, the design of design of tools for controlling gene expression at transcriptional, post-transcriptional and post-translational levels, and consider potential applications of these tools as well as the limitations of synthetic biology in the world of countermeasures.

Warfighter Integration to Enhance Operational Utility of Emerging Technologies

DTRA Session Chair: Mr. Ryan Madden

It is important to integrate the Warfighter into the new technology development pipeline early and often to ensure emerging capabilities can more effectively support critical Warfighter Combating WMD missions.  There are a number of approaches used to enhance operational utility of emerging technologies.

Warfighter Integration tools used early in the technology development process include conducting Concept of Employment studies and capturing Operational Issues/Desired Operational Capabilities to guide the future solution.  During advanced development, Early User Assessment allows for making key changes to a technology to ensure better alignment with the Warfighter’s operational needs.  And conducting an Operational Utility Assessment with the Warfighter allows for capturing the end product’s impact to the operational mission and supports more effective transition to acquisition programs.

This topic seeks presentations highlighting programs, best practices, and Warfighter engagement with a focus on:
  • Combining and enhancing technologies from across J9-CB and the broader community to demonstrate new operational capabilities
  • Aligning technologies to support real-world operational missions
  • Demonstrating practical utility to warfighters
  • Facilitating rapid transition to advanced development

 
Mobile Conference

Follow the Conference on Your Mobile Devices!

The 2017 CBD S&T site is optimized for mobile devices. Stay connected to the conference by following the cbdstconference.com link from your tablets or smartphones.

 

 DTRA.mil      DTRA YouTube       DTRA DVIDS      CBD S&T 2015 Conference   Website powered by Navar, Inc.